NewsBenzingaエボムヌは、モデレイトからシビアなアトピック皮膚炎におけるEVO301の第2a相研究結果を欧州皮膚科学・性病学アカデミーの学会で発表します。 エボムヌは、モデレイトからシビアなアトピック皮膚炎におけるEVO301の第2a相研究結果を欧州皮膚科学・性病学アカデミーの学会で発表します。 Benzinga 2026.09.23 20:06 (GMT+0) Open on Benzinga Other news AEON Biopharma Q3 EPS $0.01 Beats $(0.08) Estimate STOP-HS1 And STOP-HS2 Trials Evaluating Safety And Efficacy Of Povofortay In Patients With Moderate To Severe HS Met The Primary Endpoint Cable One Receives Non-Compliance Notice From NYSE Cadiz Q3 EPS $(0.18) Misses $(0.14) Estimate, Sales $1.572M Miss $2.710M Estimate MDU Resources Anticipates Issuing Equity Of ~$70M In 2027 And $100M In 2028 To Support Near-Term Capital Expenditures PagSeguro Digital Q3 Adj. EPS $0.43 Beats $0.41 Estimate, Sales $989.696M Miss $996.200M Estimate
STOP-HS1 And STOP-HS2 Trials Evaluating Safety And Efficacy Of Povofortay In Patients With Moderate To Severe HS Met The Primary Endpoint
MDU Resources Anticipates Issuing Equity Of ~$70M In 2027 And $100M In 2028 To Support Near-Term Capital Expenditures